Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cortical remyelination: A new target for repair therapies in multiple sclerosis.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis.
Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles.
The role of the sema4D/CD72-dependent signal in the regulation of B-cell activity in multiple sclerosis.
Paradoxical inflammation induced by anti-TNF agents in patients with IBD.
Blockade of CD127 Exerts a Dichotomous Clinical Effect in Marmoset Experimental Autoimmune Encephalomyelitis.
Primaquine treatment suppresses experimental autoimmune encephalomyelitis severity.
Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis.
Therapeutics to Promote CNS Repair: A Natural Human Neuron-Binding IgM Regulates Membrane-Raft Dynamics and Improves Motility in a Mouse Model of Multiple Sclerosis.
Quality of life outcomes following surgery for patients with coexistent cervical stenosis and multiple sclerosis.
Passive Experimental Autoimmune Encephalomyelitis in C57BL/6 with MOG: Evidence of Involvement of B Cells.
Functional connectivity analyses using emulated and conventional resting state data: Parts vs. the whole story.
Management of disease modifying treatments in neurological autoimmune diseases of the central nervous system.
ISENTRESS® prescribing information
The immunogenetics of multiple sclerosis: A comprehensive review.
New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.
Alemtuzumab and multiple sclerosis: Is it safe?
PDE4B as a microglia target to reduce neuroinflammation.
A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis.
Gait and six-minute walk performance in persons with multiple sclerosis.
[Therapy adherence to immunomodulator treatment in patients with multiple sclerosis].
Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.
Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.
Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions.

Pages